Novel biotherapeutics for the prevention and control of Campylobacter spp. in chickens

点击翻译按钮获取中文摘要

The most important food-poisoning bacterium both in terms of incidence and in the damage that it causes is Campylobacter. In the UK, out of an estimated one million cases of foodborne disease each year, Campylobacter is responsible for up to 750,000 cases, 22,000 hospitalisations and 110 deaths. Current estimates by the Food Standards Agency indicate that the cost of human campylobacteriosis in the UK is around £1B, out of a total of around £1.5B for all foodborne infections. Campylobacter is found in the gastrointestinal tracts of animals destined for human consumption, with faecal contamination of meat during processing a recognised route of transmission to humans. Up to 80% of raw chicken sold in the UK is contaminated with Campylobacter, and studies suggest that the consumption of poultry is responsible for 50-70% of all endemic infections that are reported. The current level of contamination of raw poultry on sale in the UK presents an unacceptably high public health burden, and the number of human campylobacteriosis cases continues to increase. Alternative strategies are needed to reduce Campylobacter in chickens and the associated disease burden in humans.Once a chicken is colonised with Campylobacter, antibodies against the bacterium are generated and a decrease in the number of Campylobacter colonising the intestinal tract has been observed. These data suggest that passive immunotherapy using anti-Campylobacter antibodies could be an approach for interfering with colonisation in chickens. The approach could also benefit humans and other animals. This is supported by the evidence that, in the general population, humoral immune response to a number of Campylobacter antigens is developed in most people upon infection, and epidemiological studies indicate that the immunity is crucial for the development of protection against Campylobacter disease.Antibody fragments or similar small peptide molecules are under-used as therapeutics. We contend that they have potential as therapeutic and prophylactic treatments for chickens, humans and other animals against Campylobacter. We propose to use antibody library technologies, protein-directed panning and early engagement of functional screens to identify single-chain Fvs (scFvs) that block or impair the activity of Campylobacter proteins. We plan to deliver the molecules via a harmless probiotic bacterium, Bacillus subtilis, either in vegetative cell or spore form, that has been genetically altered to synthesise or release the antibody fragment in situ within the chicken gastrointestinal tract, thus providing a continuous source of scFv in vivo for therapeutic and prophylactic applications. This local in situ production of scFv has many advantages over delivery of the same reagent by conventional means. For example, removing downstream processing steps, reducing the cost of goods, and doing away with any requirement for complex dosing regimens or delivery vehicles. Such a therapeutic could be delivered in food or drink. Alternatively, the bacteria and/or bacterial spores could be used to produce the scFv(s) cheaply and easily for more traditional methods of drug delivery.